10-Q · May 11, 2026
Accendra Health reported Q1 2026 results with net revenue of $627.8 million, missing the consensus estimate of $641.5 million, while the loss per share was $0.08, beating the estimate of a $0.09 loss. The company…
Earnings analysis · 10-Q
ACH earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
Accendra Health reported a weak second quarter, with revenue of $613.2 million below the $628.1 million estimate and GAAP EPS of negative $1.16 versus the negative $0.10 estimate. Management’s 2026 outlook remains…
Read full summary
Accendra Health reported a weak second quarter, with revenue of $613.2 million below the $628.1 million estimate and GAAP EPS of negative $1.16 versus the negative $0.10 estimate. Management’s 2026 outlook remains dependent on revenue of $2.45 billion-$2.55 billion, adjusted EBITDA of $300 million-$320 million, and free cash flow only at breakeven to slightly positive levels. Debt reduction of $385 million is constructive, but the 9.000% and 9.750% secured notes and weak earnings outlook keep financial risk elevated. No material changes to the 2025 Form 10-K risk factors were reported.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.16
What stood out
-
Revenue missed consensus
Second-quarter revenue was $613.2 million, below the $628.1 million consensus estimate by approximately $14.9 million, indicating continued top-line pressure.
-
Sharp EPS miss
GAAP diluted EPS was negative $1.16 versus the negative $0.10 estimate. Adjusted EPS was negative $0.19, reflecting a materially weaker result than expected.
-
Quantitative 2026 outlook
The 2026 continuing-operations outlook calls for revenue of $2.45 billion-$2.55 billion and adjusted EBITDA of $300 million-$320 million.
-
Cash flow targeted near breakeven
Management expects 2026 free cash flow to range from breakeven to slightly positive, implying limited cash-generation capacity despite the full-year outlook.
-
Debt reduction and refinancing
Debt was reduced by $385 million, a positive balance-sheet action, while new financing includes 9.000% senior secured notes due 2032 and 9.750% senior secured notes due 2033.
-
Controls remained effective
Disclosure controls were concluded effective as of June 30, 2026, and the company reported no material change in internal control over financial reporting during the period.
What to watch
-
Revenue and earnings contraction
Revenue of $613.2 million was approximately $14.9 million below the $628.1 million consensus estimate, while adjusted EPS was negative $0.19 and GAAP EPS was negative $1.16, signaling persistent earnings and demand pressure.
-
Limited cash generation
The 2026 outlook expects free cash flow only from breakeven to slightly positive, leaving limited cushion for debt service, restructuring, or investment requirements.
-
High-cost debt structure
The capital structure includes 9.000% senior secured notes due 2032 and 9.750% senior secured notes due 2033, creating significant interest-cost and refinancing exposure.
-
No new risk-factor changes
The company stated that there were no material changes to the risk factors described in the 2025 Form 10-K through June 30, 2026; therefore, no new filing-specific risk-factor changes were identified.
Management's outlook
The company provided a 2026 continuing-operations outlook of $2.45 billion-$2.55 billion of revenue, $300 million-$320 million of adjusted EBITDA, and free cash flow ranging from breakeven to slightly positive. The filing does not provide the prior outlook, so the direction of the change cannot be determined; no numeric EPS outlook was provided.
Earlier filings 4
10-K · February 20, 2026
Accendra Health completed the divestiture of its Products & Healthcare Services (P&HS) business on December 31, 2025 and is now a single-segment home-health focused company. For the year ended December 31, 2025, net…
10-Q · August 11, 2025
Owens & Minor reported a net revenue of $681.9 million for the three months ended June 30, 2025, reflecting an increase of 3.9% year-over-year and a net loss of $869.1 million primarily due to losses from discontinued…
10-Q · May 3, 2024
Owens & Minor reported revenue of $2,612,680 (in thousands) for the quarter ended March 31, 2024, up $89,831 (3.6%) versus $2,522,849 in Q1 2023. Gross profit improved to $535,529 (up $38,222, +7.7%) and gross margin…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.